Anteris Technologies Global Corp美股票招股说明书(2026-01-22版)

Common Stock We are offering 34,782,609 of shares of our common stock, par value $0.0001 per share (“Common Stock”), pursuant to thisprospectus supplement and the accompanying prospectus. The public offering price for each share of Common Stock is $5.75. Concurrently with this offering, pursuant to a stock purchase agreement dated January 20, 2026 (the “Stock PurchaseAgreement”), we have agreed to sell to Covidien Group S.à r.l., a wholly-owned subsidiary of Medtronic plc (the “Investor”),15,652,173shares of Common Stock, at a price per share equal to the public offering price in this offering. The PrivatePlacement is being conducted pursuant to the exemption provided under Section 4(a)(2) of the Securities Act of 1933, asamended (the “Securities Act”), and, as such, the securities offered thereby are not being registered pursuant to this prospectus Our Common Stock is listed on the Nasdaq Global Market (“Nasdaq”) under the symbol “AVR.” Our CHESS DepositaryInterests over our Common Stock (“CDIs”) trade on the Australian Securities Exchange (the “ASX”) under the symbol“AVR.” On January 20, 2026, the closing price for our Common Stock on Nasdaq was $5.75 per share. Investing in our Common Stock involves a high degree of risk. See the sections titled “Risk Factors” beginning on pageS-8of this prospectus supplement and in the documents incorporated by reference in this prospectus supplement and (1)See the section of this prospectus supplement titled “Underwriting” for additional disclosure regarding underwriting discounts,commissions and expenses. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved ofthese securities or passed upon the adequacy or accuracy of this prospectus supplement or the accompanyingprospectus. Any representation to the contrary is a criminal offense. The underwriters expect to deliver the securities to purchasers on or about January22, 2026. Barclays* Prospectus Supplement ABOUT THIS PROSPECTUS SUPPLEMENTS-iiPROSPECTUS SUPPLEMENT SUMMARYS-1THE COMPANYS-1RECENT DEVELOPMENTSS-4 TABLE OF CONTENTS ABOUT THIS PROSPECTUS SUPPLEMENT This prospectus supplement describes the specific terms of this offering and adds to and updates informationcontained in the accompanying prospectus. The accompanying prospectus provides more general information, someof which may not apply to this offering. Generally, when we refer to this prospectus, we are referring to thisprospectus supplement and the accompanying prospectus combined. To the extent there is a conflict between the This prospectus forms a part of a registration statement on FormS-3 that we have filed with the Securities andExchange Commission (the “SEC”) utilizing a “shelf” registration process. You should read this prospectus and therelated exhibits filed with the SEC, together with the additional information described under the headings “Where Neither we nor the underwriters have authorized anyone to provide you with any information other than theinformation contained or incorporated by reference in this prospectus supplement or the accompanying prospectus orany free writing prospectus prepared by or on behalf of us in connection with this offering to which we have referredyou. We and the underwriters take no responsibility for, and can provide no assurances as to the reliability of, anyother information that others may give you. The information contained in this prospectus supplement or theaccompanying prospectus, or incorporated by reference herein or therein, or in any such free writing prospectusprovided in connection with this offering is accurate only as of the date thereof, regardless of the time of delivery of Neither we nor the underwriters are offering to sell, or seeking offers to buy, our Common Stock in any jurisdictionswhere offers and sales are not permitted. The distribution of this prospectus supplement and the accompanyingprospectus and the offering of our Common Stock in certain jurisdictions may be restricted by law. Persons outsidethe United States who come into possession of this prospectus supplement and the accompanying prospectus mustinform themselves about, and observe any restrictions relating to, the offering of our Common Stock and the In this prospectus supplement, unless otherwise indicated or the context otherwise requires, all references in thisprospectus to the “Company,” “Anteris,” “Anteris®,” “we,” “us” and “our” refer to Anteris Technologies Pty Ltd(formerly Anteris Technologies Ltd) (“ATPL”) prior to the Reorganization (as defined herein) and Anteris TABLE OF CONTENTS This summary highlights selected information, some of which is presented in greater detail elsewhere in thisprospectus supplement or incorporated by reference herein. It does not contain all of the information that may beimportant to you and your investment decision. Before investing in our Common Stock, you should carefully readthis entire prospectus supplement and th